GPER-1 and estrogen receptor-β ligands modulate aldosterone synthesis

Endocrinology (United States)

Volumn 155, Issue 11, 2014, Pages 4296-4304

  Caroccia, Brasilina ^a   Seccia, Teresa M ^a   Campos, Abril Gonzalez ^a   Gioco, Francesca ^a   Kuppusamy, Maniselvan ^a   Ceolotto, Giulio ^a   Guerzoni, Eugenia ^a   Simonato, Francesca ^a   Mareso, Sara ^a   Lenzini, Livia ^a   Fassina, Ambrogio ^a   Rossi, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 1; MESSENGER RNA; UNCLASSIFIED DRUG; ESTRADIOL; ESTROGEN RECEPTOR; GPER PROTEIN, HUMAN; LIGAND;

ADRENAL CORTEX; ADRENAL CORTEX CELL; ADULT; ALDOSTERONE RELEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIMARY HYPERALDOSTERONISM; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFANT; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL CULTURE;

ADRENAL CORTEX; ALDOSTERONE; ESTRADIOL; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFANT; LIGANDS; MALE; METABOLIC NETWORKS AND PATHWAYS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; TUMOR CELLS, CULTURED;

EID: 84908043040     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1416     Document Type: Article

References (37)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther. 2012;135:54-70.
3. Kappert K, Böhm M, Schmieder R, et al. ONTARGET/TRANSCEND Investigators. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012;126:934-941.
4. Denton KM, Hilliard LM, Tare M. Sex-related differences in hypertension: seek and ye shall find. Hypertension. 2013;62:674-677.
5. Coleman KM, Smith CL. Intracellular signaling pathways: non-genomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci. 2001;6:D1379-D1391.
6. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997;45:607-617.
7. Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol. 2014;389:71-83
8. McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18:1429-1433.
9. Rossi GP, Belfiore A, Bernini G, et al. Primary Aldosteronism Prevalence in Hypertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008;93:2566-2571.
10. Rossi GP, Bernini G, Caliumi C, et al. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
11. Rossi GP, Seccia TM. Changes in aldosterone and obesity-related cardiometabolic risk factors with a 1-year weight loss intervention in normotensive overweight and obese young adults. Hypertens Res. 2013;36:856-858.
12. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension. 2008;51:1252-1258.
13. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
15. Ye P, Mariniello B, Mantero F, Shibata H, Rainey WE. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol. 2007;195:39-48.
16. Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F, Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol. 2009;160:443-451.
17. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012;59:592-598.
18. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772.
19. de Cremoux P, Rosenberg D, Goussard J, et al. Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease. Endocr Relat Cancer. 2008;15:465-474.
20. Sasano H, Matsuzaki S, Suzuki T. Estrogen receptor mRNA in situ hybridization using microprobe system. Methods Mol Biol. 2001;176:317-325.
21. Baquedano MS, Saraco N, Berensztein E, et al. Identification and developmental changes of aromatase and estrogen receptor expression in prepubertal and pubertal human adrenal tissues. J Clin Endocrinol Metab. 2007;92:2215-2222.
22. Montanaro D, Maggiolini M, Recchia AG, et al. Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation. J Mol Endocrinol. 2005;35:245-256.
23. Fassina A, Cappellesso R, Simonato F, Lanza C, Marzari A, Fassan M. Fine needle aspiration of non-small cell lung cancer: current state and future perspective. Cytopathology. 2012;23:213-219.
24. Jang JH, Hanash S. Profiling of the cell surface proteome. Proteomics. 2003;3:1947-1954.
25. Caroccia B, Fassina A, Seccia TM, et al. Isolation of human adrenocortical aldosterone-producing cells by a novel immunomagnetic beads method. Endocrinology. 2010;151:1375-1380.
26. Parmar J, Key RE, Rainey WE. Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab. 2008;93:4542-4546.
27. Ceolotto G, Valente R, Baritono E, et al. Effect of insulin and angiotensin II on cell calcium in human skin fibroblasts. Hypertension. 2001;37:1486-1491.
28. Shigematsu K, Nakagaki T, Yamaguchi N, Kawai K, Sakai H, Takahara O. Analysis of mRNA expression for steroidogenic enzymes in the remaining adrenal cortices attached to adrenocortical adenomas. Eur J Endocrinol. 2008;158:867-878.
29. Shigematsu K, Nishida N, Sakai H, et al. Primary aldosteronism with aldosterone-producing adenoma consisting of pure zona glomerulosa-type cells in a pregnant woman. Endocr Pathol. 2009;20:66-72.
30. Barzon L, Masi G, Pacenti M, et al. Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch. 2008;452:181-191.
31. Yanes LL, Romero DG. Dihydrotestosterone stimulates aldosterone secretion by H295R human adrenocortical cells. Mol Cell Endocrinol. 2009;303:50-56.
32. Rossi GP. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it? Hypertens Res. 2011;34:43-46.
33. Schunkert H, Danser AH, Hense HW, Derkx FH, Kürzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation. 1997;95:39-45.
34. Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Reckelhoff JF. Postmenopausal hypertension: role of the renin-angiotensin system. Hypertension. 2010;56:359-363.
35. Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab. 2011;96:E340-E346.
36. Wenner MM, Stachenfeld NS. Blood pressure and water regulation: understanding sex hormone effects within and between men and women. J Physiol. 2012;590:5949-5961.
37. Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20:596-604.